Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

AZ’s bet on Daiichi’s rival to Kadcyla pays off

drug trio alongside Herceptin (trastuzumab) and Perjeta (pertuzumab).

Hemlibra off to a flyer as Roche raises 2019 forecasts

It’s looking likely to overtake Roche’s older breast cancer Perjeta (pertuzumab), which rose 41% to CHF 868m in the quarter and has been another big growth driver for the
AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

trastuzumab) and Perjeta (pertuzumab), and have disease progression after Kadcyla treatment. ... That is however well behind the $7bn and $2.8bn added to the company’s coffers by Herceptin and Perjeta.
Biosimilar Herceptin helps Roche gain new Perjeta recommendation

now recommendation of a new use for Perjeta will make the NHS an early adopter. ... Richard Erwin, Roche UK's general manager (pictured) said: “Roche has worked closely with NICE and other health stakeholders to help make Perjeta available as quickly
Roche submits Kadcyla for FDA Real-Time review

Herceptin and follow-up Perjeta are already approved for neoadjuvant use in this indication, but it doesn’t always clear away all tumour tissue, which could dramatically increase the risk of
Ocrevus helps Roche shrug off biosimilars in 2018

All told, new products accounted for 90% of Roche’s sales growth in 2018, with another big boost provided by the company’s breast cancer drug Perjeta (pertuzumab), up 27% to

More from news
Approximately 17 fully matching, plus 45 partially matching documents found.

Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Add my company

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...